Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up

Small and large animal models in cardiac contraction research: Advantages and disadvantages

(2013) Nima Milani-Nejad et al.   PHARMACOLOGY & THERAPEUTICS

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

(2012) Martin Štěrba et al.   ANTIOXIDANTS & REDOX SIGNALING

Anthracycline cardiotoxicity

(2011) Pierantonio Menna et al.   Expert Opinion On Drug Safety

Proteomic insights into chronic anthracycline cardiotoxicity

(2011) Martin Štěrba et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

The role of the proteasome in heart disease

(2010) Yi-Fan Li et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?

(2010) Douglas B. Sawyer et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

(2009) O Popelová et al.   BRITISH JOURNAL OF CANCER

Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte Death

(2009) Satoru Kobayashi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

(2008) A. Palumbo et al.   ANNALS OF ONCOLOGY